Gardasil approved to prevent anal cancer

FDA: Gardasil approved to prevent anal cancer – The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

Screening for cervical cancer too frequently

Many clinicians may be screening for cervical cancer too frequently — Many physicians reported overscreening women by using both the HPV and Pap tests annually. – Many physicians reported overscreening women by using both the HPV and Pap tests annually. Clinical guidelines recommend screening low-risk women for cervical cancer every three years after age 30.

Frequent screening for women over 41 is low after HPV Vaccination

Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low – The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute.

Benefit to women not enough to sway men to get HPV vaccine

Study: Benefit to women not enough to sway men to get HPV vaccine – Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.

Gardasil is eligible for UN immunization programs

GARDASIL? is First Cervical Cancer Vaccine to Receive WHO Pre-qualification — WHO Pre-qualification Will Help to Facilitate Expanded Global Access and Implementation of HPV Vaccination Programs. – GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck’s cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL is the first cervical cancer vaccine to receive WHO pre-qualification.

Gardasil efficacious against HPV 16 infection

Studies of GARDASIL, Merck’s Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference – In a study of an extended follow up of 290 women na?ve to HPV type 16, the HPV 16 component of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration.

Do NOT follow this link or you will be banned from the site!